CIRRH
MCID: LVR012
MIFTS: 67

Liver Cirrhosis (CIRRH)

Categories: Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Liver Cirrhosis

MalaCards integrated aliases for Liver Cirrhosis:

Name: Liver Cirrhosis 12 75 29 55 6 44 15 38 72
Cirrhosis 12 74 55 43 15 40 72
Cirrhosis of Liver 12 17
Cirrhosis, Cryptogenic 72
Cryptogenic Cirrhosis 74
Cirrh 74

Classifications:



External Ids:

Disease Ontology 12 DOID:5082
MeSH 44 D008103
NCIt 50 C2951
SNOMED-CT 68 19943007
ICD10 33 K74.60
UMLS 72 C0023890 C0267809 C1623038

Summaries for Liver Cirrhosis

MedlinePlus : 43 Cirrhosis is scarring of the liver. Scar tissue forms because of injury or long-term disease. Scar tissue cannot do what healthy liver tissue does - make protein, help fight infections, clean the blood, help digest food and store energy. Cirrhosis can lead to Easy bruising or bleeding, or nosebleeds Swelling of the abdomen or legs Extra sensitivity to medicines High blood pressure in the vein entering the liver Enlarged veins called varices in the esophagus and stomach. Varices can bleed suddenly. Kidney failure Jaundice Severe itching Gallstones A small number of people with cirrhosis get liver cancer. Your doctor will diagnose cirrhosis with blood tests, imaging tests, or a biopsy. Cirrhosis has many causes. In the United States, the most common causes are chronic alcoholism and hepatitis. Nothing will make the scar tissue disappear, but treating the cause can keep it from getting worse. If too much scar tissue forms, you may need to consider a liver transplant. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Liver Cirrhosis, also known as cirrhosis, is related to alcoholic liver cirrhosis and hepatic encephalopathy, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Cirrhosis is KRT8 (Keratin 8), and among its related pathways/superpathways are Lung fibrosis and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Magnesium oxide and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include Bone and Blood, and related phenotype is liver/biliary system.

UniProtKB/Swiss-Prot : 74 Cirrhosis: A liver disease characterized by severe panlobular liver-cell swelling with Mallory body formation, prominent pericellular fibrosis, and marked deposits of copper. Clinical features include abdomen swelling, jaundice and pulmonary hypertension.

Wikipedia : 75 Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, is a condition in which the liver does... more...

Related Diseases for Liver Cirrhosis

Diseases related to Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1540)
# Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 35.5 SLC17A5 F2 ALB AFP
2 hepatic encephalopathy 33.9 SLC17A5 GPT F2 ALB
3 portal hypertension 33.0 GPT F2 EDN1 ALB
4 hepatic coma 33.0 GPT F2 ALB
5 cryptogenic cirrhosis 32.8 KRT8 KRT18 HFE F2
6 esophageal varix 32.7 SERPINC1 F2 ALB AFP
7 hepatorenal syndrome 32.5 REN F2 EDN1 ALB
8 hypersplenism 32.4 SERPINC1 F2 ALB
9 portal vein thrombosis 32.4 SERPINC1 F2 AFP
10 hepatitis b 32.3 SLC17A5 GPT F2 ALB AFP
11 acute kidney failure 32.0 REN HGF ALB
12 cholangitis 32.0 GPT F2 ALB
13 endocarditis 31.8 SERPINC1 F2 ALB
14 alpha-1-antitrypsin deficiency 31.8 SERPINC1 SERPINA1 HFE ALB
15 autoimmune hepatitis 31.8 KRT8 GPT F2
16 bilirubin metabolic disorder 31.8 SLC17A5 GPT F2 ALB
17 homocysteinemia 31.6 SERPINC1 F2 ALB
18 wilson disease 31.6 HFE GPT F2 ALB
19 acute liver failure 31.6 SLC17A5 HGF GPT F2 ALB
20 hepatitis e 31.6 GPT F2 ALB
21 antipyrine metabolism 31.6 F2 ALB
22 choledocholithiasis 31.6 SLC17A5 GPT F2 ALB
23 arteries, anomalies of 31.5 SERPINC1 REN EDN1 ALB
24 pulmonary embolism 31.5 SERPINC1 F2 ALB
25 infantile liver failure syndrome 1 31.4 SLC17A5 GPT F2 ALB
26 biliary atresia 31.4 HGF GPT ALB
27 hepatitis a 31.4 SERPINA1 GPT F2 ALB AFP
28 obstructive jaundice 31.4 SLC17A5 REN HGF GPT F2 EDN1
29 vascular disease 31.3 SERPINC1 REN F2 EDN1 ALB
30 alcoholic hepatitis 31.3 SLC17A5 KRT18 GPT F2 ALB
31 cholecystitis 31.3 KRT18 GPT F2 ALB
32 dysfibrinogenemia 31.2 SERPINC1 F2 ALB
33 viral hepatitis 31.2 SLC17A5 SERPINA1 KRT18 HFE GPT F2
34 fascioliasis 31.2 SLC17A5 GPT ALB
35 hepatitis 31.2 SLC17A5 KRT8 KRT18 GPT F2 AFP
36 peripheral vascular disease 31.2 SERPINC1 F2 ALB
37 kwashiorkor 31.2 SLC17A5 GPT F2 ALB
38 abdominal tuberculosis 31.1 F2 ALB
39 biliary tract disease 31.1 F2 ALB AFP
40 epstein-barr virus hepatitis 31.0 F2 ALB
41 hepatoportal sclerosis 31.0 GPT F2
42 compartment syndrome 31.0 SLC17A5 F2 ALB
43 congenital hepatic fibrosis 31.0 SLC17A5 REN
44 constrictive pericarditis 30.9 SERPINA1 ALB
45 renal hypertension 30.9 REN EDN1 ALB
46 analbuminemia 30.9 SLC17A5 GPT F2 ALB
47 eclampsia 30.9 SERPINC1 REN F2 EDN1 ALB
48 fatty liver disease, nonalcoholic 1 30.9 SLC17A5 KRT18 GPT
49 bile duct disease 30.9 GPT F2 ALB AFP
50 pulmonary edema 30.8 REN F2 EDN1

Graphical network of the top 20 diseases related to Liver Cirrhosis:



Diseases related to Liver Cirrhosis

Symptoms & Phenotypes for Liver Cirrhosis

UMLS symptoms related to Liver Cirrhosis:


nausea and vomiting, constipation, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Liver Cirrhosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.17 AFP ALB HFE HGF KRT18 KRT8

Drugs & Therapeutics for Liver Cirrhosis

Drugs for Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 774)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium oxide Approved Phase 4 1309-48-4 14792
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
4
Insulin glulisine Approved Phase 4 207748-29-6
5
Nadolol Approved Phase 4 42200-33-9 39147
6
acetic acid Approved Phase 4 64-19-7 176
7
Carboplatin Approved Phase 4 41575-94-4 10339178 498142 38904
8
Azithromycin Approved Phase 4 83905-01-5 447043 55185
9
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 5310940 9887054 43805 6857599
10
Liraglutide Approved Phase 4 204656-20-2 44147092
11
Prazosin Approved Phase 4 19216-56-9 4893
12
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
13
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
14
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
15
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
16
Thrombin Approved, Investigational Phase 4
17
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
18
Colchicine Approved Phase 4 64-86-8 6167 2833
19
Simvastatin Approved Phase 4 79902-63-9 54454
20
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
21
Insulin Lispro Approved Phase 4 133107-64-9
22
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
23
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
24
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
25
Zidovudine Approved Phase 4 30516-87-1 35370
26
Dalteparin Approved Phase 4 9005-49-6
27
Norepinephrine Approved Phase 4 51-41-2 439260
28
Phylloquinone Approved, Investigational Phase 4 84-80-0
29
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
30
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
31
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
32
Losartan Approved Phase 4 114798-26-4 3961
33
Methylene blue Approved, Investigational Phase 4 61-73-4
34
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
35
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
36
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
37
Insulin Detemir Approved Phase 4 169148-63-4 5311023
38
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
39
Insulin Aspart Approved Phase 4 116094-23-6 16132418
40
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
41
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
42
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
43
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
44
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
45
Nicotine Approved Phase 4 54-11-5 942 89594
46
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
47
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
48
Nelfinavir Approved Phase 4 159989-64-7 64143
49
Meperidine Approved Phase 4 57-42-1 4058
50 Bemiparin Approved, Investigational Phase 4 91449-79-5

Interventional clinical trials:

(show top 50) (show all 2467)
# Name Status NCT ID Phase Drugs
1 A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
2 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
3 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
4 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
5 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
6 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
7 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
8 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
9 Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems Unknown status NCT00332904 Phase 4 propranolol;spironolactone
10 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
11 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
12 A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
13 Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
14 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
15 Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
16 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
17 Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis – a Prospective Randomized Long-Term Study Unknown status NCT00239096 Phase 4 losartan (drug)
18 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
19 Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Comparing Carvedilol and Endoscopic Therapy: A Multicenter Randomized Controlled Trial Unknown status NCT02695732 Phase 4 Carvedilol
20 Propofol and Fentanyl Versus Midazolam and Fentanyl for Sedation During Diagnostic or Therapeutic Gastrointestinal Endoscopy in Cirrhotic Patients Unknown status NCT00906139 Phase 4 Propofol;Midazolam;Fentanyl
21 The Effect of Carvedilol Vs Propranolol in Patients With Cirrhosis Related Esophagogastric Varices After Multiple Endoscopic Treatments For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
22 Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Unknown status NCT02074280 Phase 4 rifaximin
23 Rifaximin Reduces the Complications of Decompensated Cirrhosis Unknown status NCT02190357 Phase 4 Rifaximin
24 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial Unknown status NCT01298284 Phase 4 propranolol
25 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
26 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
27 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
28 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
29 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
30 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
31 The Effect of HVPG-Guided Individualized Therapy in Patients With Cirrhosis Related Esophagogastric Variceal Hemorrhage For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02638415 Phase 4 Carvedilol
32 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
33 RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
34 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
35 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
36 Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy Unknown status NCT01165567 Phase 4 sarpogrelate
37 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
38 A Randomized Trial of GVS Alone vs. Nadolol Unknown status NCT01298271 Phase 4 propranolol
39 The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers Unknown status NCT01133184 Phase 4
40 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
41 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
42 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
43 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
44 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
45 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
46 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
47 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
48 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
49 Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
50 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin

Search NIH Clinical Center for Liver Cirrhosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Bumetanide
Ethacrynate Sodium
Ethacrynic Acid
Furosemide
Hydrochlorothiazide
Milk thistle extract
Peginterferon alfa-2a
torsemide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Cirrhosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Cirrhosis:
Autologous bone marrow-derived mesenchymal stem cells for liver cirhosis
Autologous bone marrow-derived stem cells for treatment of liver cirrhosis
Autologous hematopoietic stem cells for treatment of end-stage chronic liver disease
Bone marrow-derived endothelial progenitor cells for advanced liver cirrhosis
Bone marrow-derived mesenchymal stem cells for treatment of cirrhosis-related refractory ascites
Bone marrow-derived mesenchymal stem cells for treatment of liver cirrhosis
Hepatocyte transplantation for treatment of liver failure and inherited metabolic diseases
Mesenchymal stem cells for liver cirrhosis
NU215-01, human umbilical cord mesenchymal stem cells for treatment of liver cirrhosis
Peripheral blood-derived CD34+ or mononuclear cells for liver cirrhosis
StempeucelLC, mesenchymal stem cells for liver cirrhosis
Umbilical cord-derived mesenchymal stem cells for treatment of liver cirrhosis
Embryonic/Adult Cultured Cells Related to Liver Cirrhosis:
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 21771778 22121493
Peripheral blood-derived hematopoietic stem cells PMIDs: 20587151
Bone marrow-derived endothelial progenitor cells (family)
Hepatocytes
Umbilical cord-derived mesenchymal stem cells
Peripheral blood-derived mesenchymal stem cells (family)
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 18720444
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver cirrhosis

Genetic Tests for Liver Cirrhosis

Genetic tests related to Liver Cirrhosis:

# Genetic test Affiliating Genes
1 Liver Cirrhosis 29

Anatomical Context for Liver Cirrhosis

MalaCards organs/tissues related to Liver Cirrhosis:

41
Liver, Testes, Bone, Kidney, Spleen, Heart, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Liver Cirrhosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Liver Sinusoids Hepatic Stellate Cells Affected by disease
4 Liver Liver Lobule Hepatocytes Affected by disease
5 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
6 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Liver Cirrhosis

Articles related to Liver Cirrhosis:

(show top 50) (show all 46831)
# Title Authors PMID Year
1
Mutation of human keratin 18 in association with cryptogenic cirrhosis. 9 38 71
9011570 1997
2
Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies. 9 71
12724528 2003
3
Keratin 8 mutations in patients with cryptogenic liver disease. 9 71
11372009 2001
4
Mig chemokine in primary biliary cirrhosis. 38 17
31173052 2019
5
The role and indications of albumin in advanced liver disease. 17
31314192 2019
6
Autoimmune liver disease (primary biliary cholangitis/autoimmune hepatitis-overlap) associated with sarcoidosis (clinical cases and literature review). 17
31090378 2019
7
The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt. 9 38
20189618 2010
8
Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. 9 38
20428787 2010
9
Hemodynamic effects of chronic smoking in liver cirrhosis: a role for adrenomedullin. 9 38
20216319 2010
10
Splanchnic concentrations and postprandial release of visceral adipokines. 9 38
19913846 2010
11
Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. 9 38
19582578 2010
12
Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. 9 38
19920809 2010
13
Hepatic osteodystrophy and liver cirrhosis. 9 38
20355242 2010
14
Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. 9 38
20346216 2010
15
Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide. 9 38
19495975 2010
16
Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. 9 38
20357999 2010
17
Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. 9 38
20350877 2010
18
Alpha-fetoprotein gene polymorphisms and risk of HCC and cirrhosis. 9 38
19968979 2010
19
Utilization of platelet count spleen diameter ratio in predicting the presence of esophageal varices in patients with cirrhosis. 9 38
19593164 2010
20
Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume. 9 38
19406586 2010
21
Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. 9 38
19864937 2010
22
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. 9 38
19877168 2010
23
Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. 9 38
19793171 2010
24
Hepatitis B virus load in serum does not reflect histologic activity in patients with decompensated cirrhosis. 9 38
19804841 2010
25
Increased bactericidal/permeability increasing protein in patients with cirrhosis. 9 38
19765220 2010
26
[Expressions of MDM2 and MMP-7 in normal liver, cirrhosis, hepatocellular carcinoma tissues]. 9 38
20128976 2010
27
Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging. 9 38
20118733 2010
28
[Relationship between quality of life and basic syndromes of traditional Chinese medicine in patients with posthepatitic cirrhosis]. 9 38
20082755 2010
29
Severe sepsis in cirrhosis. 9 38
19885876 2009
30
[Monitoring patients with chronic hepatitis during and after therapy]. 9 38
20198895 2009
31
Resolution of preoperative portal vein thrombosis after administration of antithrombin III in living donor liver transplantation: case report. 9 38
19917415 2009
32
Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis. 9 38
20214224 2009
33
IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. 9 38
19797428 2009
34
A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis. 9 38
19676133 2009
35
Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. 9 38
19243500 2009
36
Correlation of routinely used coagulation parameters and presence of portal vein thrombosis in patients with liver cirrhosis. 9 38
19619258 2009
37
Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. 9 38
19608867 2009
38
[Analysis of prognostic factors for patients with acute-on-chronic liver failure]. 9 38
19719920 2009
39
Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases. 9 38
19294419 2009
40
Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. 9 38
19642174 2009
41
Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. 9 38
19413694 2009
42
Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. 9 38
19365625 2009
43
[Comparison of the serum proteomes of pathological stages during hepatocarcinogenesis]. 9 38
19912687 2009
44
Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. 9 38
19760951 2009
45
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. 9 38
19201777 2009
46
Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis. 9 38
19478697 2009
47
Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan. 9 38
19552764 2009
48
Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. 9 38
19207581 2009
49
Abundance of immunologically active alanine aminotransferase in sera of liver cirrhosis and hepatocellular carcinoma patients. 9 38
19264859 2009
50
Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. 9 38
19220736 2009

Variations for Liver Cirrhosis

ClinVar genetic disease variations for Liver Cirrhosis:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 FARSB NM_005687.5(FARSB): c.1381A> C (p.Thr461Pro) single nucleotide variant Pathogenic rs1396171148 2:223478611-223478611 2:222613892-222613892
2 FARSB NM_005687.5(FARSB): c.784A> G (p.Lys262Glu) single nucleotide variant Pathogenic rs1553554543 2:223496325-223496325 2:222631606-222631606
3 FARSB NM_005687.5(FARSB): c.1202G> A (p.Arg401Gln) single nucleotide variant Pathogenic rs1553553086 2:223488418-223488418 2:222623699-222623699
4 FARSB NM_005687.5(FARSB): c.755T> C (p.Phe252Ser) single nucleotide variant Pathogenic rs1466642025 2:223496354-223496354 2:222631635-222631635
5 FARSB NM_005687.5(FARSB): c.226T> C (p.Cys76Arg) single nucleotide variant Pathogenic rs1419129874 2:223507613-223507613 2:222642894-222642894
6 KRT18 NM_000224.3(KRT18): c.383A> T (p.His128Leu) single nucleotide variant Pathogenic,risk factor rs57758506 12:53343340-53343340 12:52949556-52949556
7 KRT8 NM_002273.4(KRT8): c.184G> T (p.Gly62Cys) single nucleotide variant Pathogenic,risk factor rs11554495 12:53298582-53298582 12:52904798-52904798
8 KRT8 NM_002273.4(KRT8): c.160T> C (p.Tyr54His) single nucleotide variant Pathogenic rs57749775 12:53298606-53298606 12:52904822-52904822

Copy number variations for Liver Cirrhosis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 210504 6 30400000 36600000 Copy number C4B Liver cirrhosis

Expression for Liver Cirrhosis

Search GEO for disease gene expression data for Liver Cirrhosis.

Pathways for Liver Cirrhosis

Pathways related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.13 SERPINA1 HGF EDN1
2 11.05 SERPINA1 HGF ALB AFP
3 10.78 F2 ALB AFP
4 10.34 MEG3 HOTAIR

GO Terms for Liver Cirrhosis

Cellular components related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.35 SERPINC1 SERPINA1 F2 ALB AFP
2 platelet alpha granule lumen GO:0031093 9.33 SERPINA1 HGF ALB
3 extracellular space GO:0005615 9.32 SERPINC1 SERPINA1 REN HGF HFE GPT
4 basal part of cell GO:0045178 9.26 HFE EDN1

Biological processes related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hemostasis GO:0007599 9.33 SERPINC1 SERPINA1 F2
2 regulation of blood coagulation GO:0030193 9.32 SERPINC1 F2
3 hepatocyte apoptotic process GO:0097284 9.26 KRT8 KRT18
4 acute-phase response GO:0006953 9.13 SERPINA1 HFE F2
5 cellular protein metabolic process GO:0044267 9.02 SERPINC1 SERPINA1 F2 ALB AFP

Sources for Liver Cirrhosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....